Journal
EUROPEAN JOURNAL OF OPHTHALMOLOGY
Volume 27, Issue 2, Pages 160-163Publisher
WICHTIG PUBLISHING
DOI: 10.5301/ejo.5000826
Keywords
Brinzolamide/brimonidine; Cosopt (R); Dorzolamide/timolol; Glaucoma; Simbrinza (TM); Intraocular pressure
Categories
Ask authors/readers for more resources
Purpose: To compare the efficiency of brinzolamide/brimonidine fixed combination vs the dorzolamide/timolol fixed combination. Methods: Forty-four eyes of 44 patients were divided in 2 groups treated either with dorzolamide/timolol twice a day (group A) or with brinzolamide/brimonidine twice a day (group B). Complete ophthalmic examination including Goldmann applanation tonometry was performed before treatment administration and 1, 4, 8, and 12 weeks afterwards. The intraocular pressure (IOP) was measured twice a day (morning at 9 AM and afternoon at 4 PM). Results: At the end of the follow-up period (12 weeks), mean morning IOP reduction was 7.0 +/- 2.8 mm Hg in group A and 8.4 +/- 1.9 mm Hg in group B. A significant difference was found (p = 0.0343). In contrast, mean afternoon IOP reduction was 8.6 +/- 2.7 mm Hg in group A and 7.9 +/- 1.6 mm Hg in group B and no significant difference was found (p = 0.3413). No significant adverse effects were observed in either group. Conclusions: Brinzolamide/brimonidine seems to be an effective and safe alternative alpha-blocker free fixed combination, especially for patients with comorbidities, having its own antihypertensive profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available